The healthcare sector has spent years debating AI governance. Whether AI belongs in clinical care. What hybrid oversight models look like. Who reviews what, when, and how.
That debate is largely settled now. Hybrid AI-clinician oversight models are becoming standard. Good.
But the sector is celebrating the wrong milestone.
The Upstream Problem Nobody's Fixing
I've stood behind pharmacy counters for a decade. I've watched clinical data move through documentation systems, abstraction layers, and registry pipelines before it ever reaches a decision point.
The real risk doesn't sit at the AI layer. It sits upstream, in the data pipeline itself.
By the time AI touches a decision, the data has already been handled by multiple humans, multiple systems, and multiple points of failure. Each handoff introduces interpretation drift. Each system introduces inconsistency. The model inherits all of it.
A survey of 22,889 patients revealed that 21% noticed inaccuracies in their clinical notes. Among those who identified mistakes, nearly 42% categorised them as serious. 36% of documentation errors were due to copy-pasting, which promotes dissemination of wrong or out-of-date information.
This isn't an AI problem. This is a data governance problem that existed long before we started deploying models.
Where Misinterpretation Actually Starts
Clinical data doesn't arrive clean. It moves through layers.
A GP writes notes during a consultation. Those notes get abstracted into a system. That system feeds a registry. The registry connects to another platform. Somewhere in that chain, a pharmacist reads the output and makes a dispensing decision.
Now add AI into that pipeline.
The model doesn't see the original consultation. It sees the fourth or fifth interpretation of what happened in that room. If the documentation was rushed, if the abstraction was incomplete, if the registry mapping was inconsistent, the AI inherits every single one of those problems.
Almost right is the dangerous one. Almost right passes review. Almost right ships to production. In a diagnosis, almost right is a missed margin on a scan that everyone trusted.
I've seen this in pharmacy. Prescription data that looks fine in the system but doesn't match what the patient actually needs. Stock levels that are technically correct but operationally useless. Clinical notes that say one thing but mean another.
The AI doesn't create these problems. It amplifies them.
The Validation Gap
Here's what I've noticed: many healthcare AI deployments are built on data nobody has properly validated.
The model performs well in controlled testing. Clean datasets. Structured inputs. Predictable scenarios.
Then it hits real-world deployment. Messy data. Incomplete records. Edge cases nobody anticipated.
The gap isn't the AI. It's the foundation.
McKinsey research points to fewer than 20% of healthcare AI pilots successfully transitioning to full-scale deployment. MIT's 2025 study found that 95% of AI experiments do not deliver value. The organisations stuck in perpetual pilot phases share common patterns: they invest in sophisticated AI tools whilst leaving their data foundations fragmented.
47% of healthcare leaders cite data quality and integration as major barriers to AI implementation. Not model accuracy. Not computational power. Data quality.
The sector has been so focused on governing the AI layer that it's ignored the structural problems feeding into it.
What Rigorous Data Governance Actually Looks Like
Data governance isn't a compliance checkbox. It's not a policy document that sits in a folder somewhere.
It's specific. It's structural. It's ongoing.
First, you validate at the source. Clinical documentation needs to be accurate before it enters any system. That means training, time, and tools that support proper recording. Not copy-paste workflows. Not rushed entries between patients.
Second, you map the handoffs. Every point where data moves from one system to another is a potential failure point. You need to know what's being transformed, what's being lost, and what's being assumed. If you can't trace a data point from consultation to decision, you don't have governance.
Third, you validate locally. Generic vendor validation proves insufficient for healthcare AI compliance. Organisations must validate AI tools within their specific deployment context, accounting for unique patient populations, clinical workflows, and operational environments. This requirement for local AI validation in healthcare settings is non-negotiable and ongoing.
The vast majority of medical AI is never reviewed by a federal regulator, and probably no state regulator either. With 46% of U.S. healthcare organisations currently implementing generative AI technologies, this regulatory gap creates significant liability exposure for organisations deploying AI systems without proper oversight frameworks.
Fourth, you build feedback loops. When the AI makes a decision, you need to know if it was right. Not just in aggregate metrics. In specific cases. You need clinicians reviewing outputs, flagging problems, and feeding corrections back into the system.
This isn't glamorous work. It doesn't make for exciting conference presentations. But it's the work that actually matters.
What Pharmacy Owners Should Be Asking
If you're a pharmacy owner considering AI tools, here's what you should ask before you adopt anything:
- Where does your training data come from? Not just "healthcare data." Specifically. What systems? What time period? What patient populations? If the vendor can't tell you, that's a problem.
- How do you handle data inconsistencies? Every pharmacy has different documentation standards, different stock management approaches, different workflow patterns. How does the tool account for that? If the answer is "it just works," walk away.
- What happens when the AI is wrong? Not if. When. How do you catch it? How do you correct it? How do you prevent the same mistake from happening again? If there's no clear answer, you're building on unstable ground.
- Can you validate this in your environment? Not in a demo. Not in a pilot with clean data. In your actual pharmacy, with your actual workflows, with your actual edge cases. If the vendor won't let you test properly, they're not confident in their product.
I built RxLine because I lived the problem. I know what it's like to be so busy you can't think properly. I know what it's like when systems fail and you're left holding the consequences.
That's why we don't give clinical advice. That's why we're honest about what the product can and cannot do. That's why we tell pharmacies they don't need us if their volume doesn't justify it.
Radical honesty in a space full of overclaiming isn't just a brand position. It's a recognition that getting this wrong has real consequences.
The Infrastructure Has to Come Before the Intelligence
A systematic review of 35 frameworks for AI implementation in healthcare identified seven critical domains of healthcare AI governance. Artificial intelligence in healthcare is rapidly shifting from experimental pilots to mainstream clinical infrastructure.
But here's what I've learnt: you can't govern what you can't trace. You can't validate what you can't measure. You can't trust outputs when you don't trust inputs.
The governance debate focused on the wrong layer. It asked "how do we oversee AI decisions?" when it should have asked "how do we ensure the data feeding those decisions is actually reliable?"
Until the sector takes data governance as seriously as it took the AI governance debate, we're building on unstable ground.
The infrastructure has to come before the intelligence.
I've seen what happens when systems break. I've seen pharmacists making decisions based on incomplete information because the data pipeline failed somewhere upstream. I've seen patients caught in the gap between what the system says and what's actually true.
AI doesn't fix that. Rigorous data governance does.
The sector celebrated when the governance debate concluded. But the real work is just starting. And it sits upstream, in the unglamorous, structural, essential work of ensuring clinical data is accurate, traceable, and validated before any model ever touches it.
That's the work that actually protects patients. That's the work that actually enables safe AI deployment. That's the work we should have been doing all along.